Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US7041646B2 · kind B2 · utility
33Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 16, 2003 |
| Grant date | May 9, 2006 |
| Priority date | — |
| Expiry date | Nov 5, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.